RAS guanyl releasing protein 2Genealiases: CALDAG-GEFI · CDC25L
Q-omics provides the consensus-scored RASGRP2 profile across patient tissues and cancer cell-line models. RASGRP2 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, RASGRP2 is differentially expressed in 13, with the highest sampling consensus in BLCA. Additionally, RASGRP2 protein abundance shows 25,589 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight HNSC, BLCA, and GBM as cancer lineages where RASGRP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RASGRP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RASGRP2 survival associations across molecular data types. RASGRP2 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (9) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RASGRP2 RNA expression–survival associations across cancer types. High RASGRP2 expression shows unfavorable associations in UVM, but favorable associations in HNSC, SKCM, LUAD, SARC and CESC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for RASGRP2 RNA expression.
This table summarizes RASGRP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 8. The strongest signals are observed in BLCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for RASGRP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RASGRP2 shows lower tumor expression in BLCA, KICH, LUAD, COAD, KIRP and LUSC. The BLCA box plot shows higher RASGRP2 RNA expression in normal versus tumor tissue (log2 FC = −3.222, t-test p < 0.001).
This table shows molecular features associated with RASGRP2 in patient tissues and cancer cell lines. In patient samples, RASGRP2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, RASGRP2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BONE.
